Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model

Human Gene Therapy

Volumn 22, Issue 7, 2011, Pages 843-852

  Favaro, Patricia ^a   Finn, Jonathan D ^a   Siner, Joshua I ^a   Wright, J Fraser ^a,b   High, Katherine A ^a,c,d   Arruda, Valder R ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS 5 VECTOR; ADENO ASSOCIATED VIRUS 6 VECTOR; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 5; ADENO ASSOCIATED VIRUS 6; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BIOACCUMULATION; CLEARANCE; CROSS REACTION; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; HUMORAL IMMUNITY; LIVER; LOW DRUG DOSE; MALE; NONHUMAN; PROTEIN EXPRESSION; RABBIT; SEROTYPE; SPERM; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; CAPSID; CAPSID PROTEINS; DEPENDOVIRUS; DNA, VIRAL; FACTOR IX; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIVER; MALE; MODELS, ANIMAL; RABBITS; SEMEN; TISSUE DISTRIBUTION; TRANSGENES; VIRUS SHEDDING;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2; ADENO-ASSOCIATED VIRUS - 5; ANIMALIA; MIRIDAE; ORYCTOLAGUS CUNICULUS;

EID: 79960370642     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2010.155     Document Type: Article

References (47)

1. Adams, C.E. (1987). The laboratory rabbit. In The UFAW Handbook on the Care and Management of Laboratory Animals. Poole TB, ed. (Churchill Livingstone, New York) pp. 415-435.
2. Arruda, V.R., Fields, P.A., Milner, R., et al. (2001). Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol. Ther. 4, 586-592. (Pubitemid 34026874)
3. Arruda, V.R., Stedman, H.H., Haurigot, V., et al. (2010). Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood 115, 4678-4688.
4. Bainbridge, J.W., Smith, A.J., Barker, S.S., et al. (2008). Effect of gene therapy on visual function in Leber's congenital amau-rosis. N. Engl. J. Med. 358, 2231-2239. (Pubitemid 351724452)
5. Bish, L.T., Sleeper, M.M., Brainard, B., et al. (2008). Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol. Ther. 16, 1953-1959.
6. Boutin, S., Monteilhet, V., Veron, P., et al. (2010). Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704-712.
7. Calcedo, R., Vandenberghe, L.H., Gao, G., et al. (2009). Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381-390.
8. Damjanov, I., Solter, D., and Knowles, B.B. (1993). Functional epidermal growth factor receptor localizes to the post-acrosomal region of human spermatozoa. Biochem. Biophys. Res. Commun. 190, 901-906. (Pubitemid 23207850)
9. Davidoff, A.M., Gray, J.T., Ng, C.Y., et al. (2005). Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol. Ther. 11, 875-888. (Pubitemid 40724106)
10. Di Pasquale, G., Davidson, B.L., Stein, C.S., et al. (2003). Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 9, 1306-1312. (Pubitemid 37279855)
11. Favaro, P., Downey, H.D., Zhou, J.S., et al. (2009). Host and vector-dependent effects on the risk of germline transmission of AAV vectors. Mol. Ther. 17, 1022-1030.
12. Gao, G., Alvira, M., Wang, L., et al. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859. (Pubitemid 34994488)
13. Gao, G., Lu, Y., Calcedo, R., et al. (2006). Biology of AAV sero-type vectors in liver-directed gene transfer to nonhuman primates. Mol. Ther. 13, 77-87. (Pubitemid 41763485)
14. Grimm, D., Zhou, S., Nakai, H., et al. (2003). Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102, 2412-2419. (Pubitemid 37193577)
15. Halbert, C.L., Miller, A.D., McNamara, S., et al. (2006). Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum. Gene Ther. 17, 440-447.
16. Hauswirth, W.W., Aleman, T.S., Kaushal, S., et al. (2008). Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. Hum. Gene Ther. 19, 979-990.
17. Jiang, H., Couto, L.B., Patarroyo-White, S., et al. (2006a). Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108, 3321-3328.
18. Jiang, H., Lillicrap, D., Patarroyo-White, S., et al. (2006b). Mul-tiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108, 107-115. (Pubitemid 43990618)
19. Jiang, H., Pierce, G.F., Ozelo, M.C., et al. (2006c). Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther. 14, 452-455. (Pubitemid 44184967)
20. Le, M., Okuyama, T., Cai, S.R., et al. (1997). Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood 89, 1254-1259. (Pubitemid 27079989)
21. Maguire, A.M., High, K.A., Auricchio, A., et al. (2009). Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 374, 1597-1605.
22. Maguire, A.M., Simonelli, F., Pierce, E.A., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248. (Pubitemid 351724453)
23. Manno, C.S., Chew, A.J., Hutchison, S., et al. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972. (Pubitemid 36857981)
24. Manno, C.S., Pierce, G.F., Arruda, V.R., et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347. (Pubitemid 43355084)
25. Mariani, S., Basciani, S., Arizzi, M., et al. (2002). PDGF and the testis. Trends Endocrinol. Metab. 13, 11-17. (Pubitemid 36734010)
26. Matsushita, T., Elliger, S., Elliger, C., et al. (1998). Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5, 938-945. (Pubitemid 28371911)
27. McCarty, D.M., Monahan, P.E., and Samulski, R.J. (2001). Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8, 1248-1254. (Pubitemid 32780813)
28. Miao, C.H., Ohashi, K., Patijin, G.A., et al. (2000). Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol. Ther. 1, 522-532.
29. Mingozzi, F., Schüttrumpf, J., Arruda, V., et al. (2002). Improved hepatic gene transfer by using an adeno-associated virus se-rotype 5 vector. J. Virol. 76, 10497-10502.
30. Nathwani, A.C., Davidoff, A.M., Hanawa, H., et al. (2002). Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 100, 1662-1669. (Pubitemid 34925143)
31. Nathwani, A.C., Gray, J.T., McIntosh, J., et al. (2007). Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109, 1414-1421. (Pubitemid 46239572)
32. Oliva-Hernandez, J., and Perez-Gutierrez, J.F. (2008). Localization of the epidermal growth factor (EGF) in the epididymis and accessory genital glands of the boar and functional effects on spermatozoa. Theriogenology 70, 1159-1169.
33. Scallan, C.D., Jiang, H., Liu, T., et al. (2006). Human immuno-globulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 107, 1810-1817. (Pubitemid 43289358)
34. Schuettrumpf, J., Herzog, R.W., Schlachterman, A., et al. (2005). Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 105, 2316-2323. (Pubitemid 40387025)
35. Schuettrumpf, J., Liu, J.H., Couto, L.B., et al. (2006). Inadvertent germline transmission of AAV2 vector: Findings in a rabbit model correlate with those in a human clinical trial. Mol. Ther. 13, 1064-1073. (Pubitemid 43779181)
36. Seiler, M.P., Miller, A.D., Zabner, J., and Halbert, C.L. (2006). Adeno-associated virus types 5 and 6 use distinct receptors for cell entry. Hum. Gene Ther. 17, 10-19. (Pubitemid 43100511)
37. Sommer, J.M., Smith, P.H., Parthasarathy, S., et al. (2003). Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol. Ther. 7, 122-128. (Pubitemid 36305364)
38. Stemmer, W.P. (1994). Rapid evolution of a protein in vitro by DNA shuffling. Nature 370, 389-391. (Pubitemid 24259765)
39. Wang, L., Calcedo, R., Nichols, T.C., et al. (2005). Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 105, 3079-3086.
40. Wang, L., Calcedo, R., Wang, H., et al. (2010). The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol. Ther. 18, 126-134.
41. Wang, Z., Chamberlain, J.S., Tapscott, S.J., and Storb, R. (2009). Gene therapy in large animal models of muscular dystrophy. ILAR J. 50, 187-198.
42. Wang, Z., Ma, H.I., Li, J., et al. (2003). Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 10, 2105-2111. (Pubitemid 37536759)
43. Weller, M.L., Amornphimoltham, P., Schmidt, M., et al. (2010). Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat. Med. 16, 662-664.
44. Wu, P., Xiao, W., Conlon, T., et al. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635-8647. (Pubitemid 30666714)
45. Xin, K.Q., Mizukami, H., Urabe, M., et al. (2006). Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J. Virol. 80, 11899-11910. (Pubitemid 44904340)
46. Zhong, L., Li, B., Mah, C.S., et al. (2008). Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U.S.A. 105, 7827-7832. (Pubitemid 351872723)
47. Zincarelli, C., Soltys, S., Rengo, G., and Rabinowitz, J.E. (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073-1080. (Pubitemid 351737072)